Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Epicrispr Biotechnologies is a biotechnology enterprise that focuses on epigenetic engineering.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.
Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.
Erasca is a developer of oncology drugs intended to provide precision oncology options.
Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.
Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.
Cormorant Asset Management has invested in 209 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 14 different industry categories.
Among tracked funding rounds, Oruka Therapeutics received $700.4M in a Post-IPO Equity round. Cormorant Asset Management's total known invested capital is $30.0B.
Cormorant Asset Management's average investment size is $143.6M across its portfolio of 209 companies.
Recent Cormorant Asset Management portfolio additions include Dren Bio, Aclaris Therapeutics, Epicrispr Biotechnologies, Orbis Medicines, Tyra Biosciences. These companies were founded in 2020 or later.